argenx SE (NASDAQ:ARGX) Given Average Rating of “Moderate Buy” by Brokerages

argenx SE (NASDAQ:ARGX) has been given an average recommendation of “Moderate Buy” by the twenty-one research firms that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $525.42.

ARGX has been the subject of a number of research analyst reports. Stifel Nicolaus boosted their target price on shares of argenx from $485.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Wedbush reissued an “outperform” rating and issued a $519.00 price target on shares of argenx in a research report on Wednesday, June 26th. Wells Fargo & Company increased their price target on shares of argenx from $478.00 to $542.00 and gave the stock an “overweight” rating in a research report on Monday, June 24th. Scotiabank increased their price target on shares of argenx from $402.00 to $408.00 and gave the stock a “sector perform” rating in a research report on Tuesday, March 26th. Finally, JPMorgan Chase & Co. dropped their price target on shares of argenx from $560.00 to $500.00 and set an “overweight” rating for the company in a research report on Monday, May 13th.

Hedge Funds Weigh In On argenx

Hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC boosted its stake in argenx by 420.0% in the first quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after acquiring an additional 63 shares during the last quarter. Mather Group LLC. bought a new position in argenx in the first quarter valued at approximately $38,000. FNY Investment Advisers LLC bought a new position in argenx in the fourth quarter valued at approximately $38,000. Benjamin F. Edwards & Company Inc. bought a new position in argenx in the fourth quarter valued at approximately $60,000. Finally, Lindbrook Capital LLC boosted its stake in argenx by 23.1% in the first quarter. Lindbrook Capital LLC now owns 197 shares of the company’s stock valued at $78,000 after acquiring an additional 37 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenx Stock Up 0.1 %

argenx stock opened at $435.84 on Monday. The company’s fifty day simple moving average is $389.29 and its 200-day simple moving average is $386.29. argenx has a 12 month low of $327.73 and a 12 month high of $550.76. The stock has a market cap of $25.90 billion, a P/E ratio of -77.00 and a beta of 0.64.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Monday, May 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.33). The company had revenue of $412.51 million for the quarter, compared to analysts’ expectations of $404.03 million. argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. During the same quarter in the prior year, the firm earned ($0.52) earnings per share. On average, equities research analysts expect that argenx will post -2.92 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.